Markers of bone metabolism in patients with systemic scleroderma
Abstract
The mechanism of development of osteoporosis (OP) in systemic scleroderma (SSc), despite ongoing studies on this subject, remains not completely clear.
Objective. To assess the state of bone mineral density (BMD) in patients with systemic scleroderma (SSc) and to determine the level of bone metabolism markers (osteocalcin, b-CrossLaps) in blood serum.
Methodology. We examined 65 patients with SSc: 6 (9%) men and 59 (91%) women, with an average age of 51 [39;61] years and 35 relatively healthy individuals comparable in basic anthropometric parameters with patients of the main group. The main population risk factors for osteoporosis were assessed. Bone mineral density (BMD) was assessed using dual energy X-ray absorptiometry (DXA). The level of vitamin D, osteocalcin (OC), and b-CrossLaps in blood serum was determined by enzyme immunoassay.
Results. A decrease in BMD was significantly more often observed in patients with SSc - 46 (71%) than in controls - 11 (31%). Significant risk factors for OP in SSc were the presence of menopause that occurred at an early age, low physical activity, hypovitaminosis D, probably high activity and duration of the disease. In patients with SSc, there was a significant decrease in the level of OK compared with the control; in the presence of a decrease in the BMD, the content of OK was significantly lower than with a normal BMD. Mean values of b-CrossLaps in SSc were comparable with the control; in patients with OP, the parameter was lower than in those with normal BMD.
Conclusion. OP develops significantly more often in SSc compared to the control. Risk factors for OP are early menopause, low physical activity, duration and activity of SSc. The predominance of bone formation disorders to a greater extent than bone resorption as a mechanism for the development of secondary OP was noted.
About the Authors
Yu. Yu. Ivanova
Orenburg State Medical University
Russian Federation
Russian Federation
Orenburg
O. V. Bugrova
Orenburg State Medical University
Russian Federation
Russian Federation
Orenburg
K. A. Nagornova
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Saint-Petersburg
R. I. Sayfutdinov
Orenburg State Medical University
Russian Federation
Russian Federation
Orenburg
References
1. Российские клинические рекомендации. Ревматология / под ред. Е.Л. Насонова. – М. : ГЭОТАР-Медиа, 2020. – 448 с.
2. Midol C, Wiebe E, Siegert E, Huscher D, Launay D, Hachulla E, Sobanski V, Buttgereit F. Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10).
3. Caimmi, C.; Caramaschi, P.; Barausse, G.; Orsolini, G.; Idolazzi, L.; Gatti, D.; Viapiana, O.; Adami, S.; Biasi, D.; Rossini, M. Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis. Calcif. Tissue Int. 2016, 99, 23–29.
4. Добровольская О.В., Демин Н.В., Смирнов А.В. и др. Состояние минеральной плотности кости у пациентов с системной склеродермией. Современная ревматология. 2019;13(1):58–63
5. Marighela TF, Genaro PD, Pinheiro MM et al. (2013) Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol 32, 1037–44.
6. Marot M, Valéry A, Esteve E, Bens G, Müller A, Rist S, Toumi H, Lespessailles E. Prevalence and predictive factors of osteoporosis in systemic sclerosis patients: a case-control study. Oncotarget. 2015;6(17):14865–73
7. Taylan, A.; Birlik, M.; Kenar, G.; Toprak, B.; Gundogdu, B.; Gurler, O.; Karakas, B.; Akinci, B.; Sisman, A.R. Osteoprotegrin Interacts with Biomarkers and Cytokines that Have Roles in Osteoporosis, Skin Fibrosis, and Vasculopathy in Systemic Sclerosis: A Potential Multifaceted Relationship Between OPG/ RANKL/TRAIL and Wnt Inhibitors. Mod. Rheumatol. 2019, 29, 619–624.
8. Adami, G.; Fassio, A.; Rossini, M.; Caimmi, C.; Giollo, A.; Orsolini, G.; Viapiana, O.; Gatti, D. Osteoporosis in Rheumatic Diseases. Int. J. Mol. Sci. 2019, 20, 5867.
9. Atteritano M, Sorbara S, Bagnato G, Mice- li G, Sangari D, Morgante S, Visalli E, Bagna- to G. Bone mineral density, bone turnover markers and fractures in patients with systemic sclerosis: a case control study. PLoS One. 2013;8(6):e66991. doi: 10.1371/journal.pone.0066991
10. Dovio, A.; Data, V.; Carignola, R.; Calzolari, G.; Vitetta, R.; Ventura, M.; Saba, L.; Severino, A.; Angeli, A. Circulating Osteoprotegerin and Soluble RANK Ligand in Systemic Sclerosis. J. Rheumatol. 2008, 35, 2206–2213.
11. Варгина Виктория Николаевна. Остеопороз у больных системной красной волчанкой и системной склеродермией и его коррекция альфакальцидолом: дис., канд. мед. наук: 14.00.39. – Волгоградский гос. университет, Волгоград, 2005 - 238 с.
12. Lai, E.L.; Huang, W.N. Ten-Year Fracture Risk by FRAX and Osteoporotic Fractures in Patients with Systemic Autoimmune Diseases. Lupus 2019, 28, 945–953.
13. Никитинская О.А., Торопцова Н.В., Насонов Е.Л. Факторы риска остеопороза у мужчин 40 лет и старше: результаты программы «Остеоскрининг-Россия». Современная ревматология. 2018;12(3):76–81
14. Ефремова А.О., Торопцова Н.В., Добровольская О.В., Старовойтова М.Н., Десинова О.В., Никитинская О.А. Факторы риска низкой минеральной плотности костей у женщин в постменопаузе с системной склеродермией. Научно-практическая ревматология. 2021;59(5):592-598. https://doi.org/10.47360/1995-4484-2021-592-598
15. Белая Ж.Е., Белова К.Ю., Бирюкова Е.В., Дедов И.И., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза // Остеопороз и остеопатии. 2021;24 (2):4-47. doi: https://doi.org/10.14341/osteo12930. [Belaya ZE, Belova Kyu. Biryukova EV, Dedov II, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporoz & osteopatii = Osteoporosis and bone diseases. 2021;24(2):4-47. doi: https://doi.org/10.14341/osteo12930]
16. Никитюк Д.Б., Погожева А.В., Шарафетдинов Х.Х., др. «Стандарты лечебного питания» - М., 2017. – 313 с.
17. Frediani B, Baldi F, Falsetti P, Acciai C, Filip-pou G, Spreafico A, Siagri C, Chellini F, Cappe-rucci C, Filipponi P, Galeazzi M, Marcolongo R. Clinical determinants of bone mass and bone ultrasonometry in patients with systemic sclerosis. Clin Exp Rheumatol. 2004;22(3): 313-8.
18. Carbone L, Tylavsky F, Wan J, McKown K, Cheng S. Bone mineral density in scleroderma. Rheumatology (Oxford). 1999;38(4):371-2.
Review
For citations:
Ivanova YY, Bugrova OV, Nagornova KA, Sayfutdinov RI. Markers of bone metabolism in patients with systemic scleroderma. Sovremennaya Revmatologiya=Modern Rheumatology Journal. (In Russ.)
Views:
856
Email this article 